Biosensors & Metabolite Detection Patents: Top Companies 2026
Biosensors and Metabolite Detection Patents: Who Leads and Where the Claims Sit
Concentrated at the top. The top 5 assignees hold 66.4% of all 152 records in scope, and the top 10 hold 84.2% — this is a field with a narrow set of controlling filers, not a crowded open one. Filings climbed from 8 in 2017 to a peak of 17 in 2018, then settled into a lower, steadier band; the 2021-to-2024 change of 7 to 6 records (-14%) reflects that plateau rather than a collapse, and years after 2024 are still filling in under publication lag.
- 1LYGOS INC36
- 2PRECIGEN INC28
- 3NOROO IC CO LTD15
- 4NORTHWESTERN UNIV12
- 5PRESIDENT & FELLOWS OF HARVARD COLLEGE10
See the full biosensors and metabolite detection analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in biosensor and metabolite detection technology?
The assignee ranking covers 40 companies and institutions across 152 records, with a single leader holding 36 records and the top 5 combined holding 101 records (66.4% of the total). The mix includes industrial synthetic-biology firms and university technology-transfer offices, and the gap between the top 5 and the rest of the ranking is large — fifth place holds 10 records while tenth place holds only 3. This means freedom-to-operate work should focus first on the handful of assignees at the top rather than spreading review evenly across all 40.
Is patent filing activity in biosensor technology growing or slowing down?
Filings peaked in 2018 at 17 records, then settled into a lower band, with the 2021-to-2024 window showing a -14% change (7 records down to 6). That is a plateau rather than a decline, and 2024 is the last year in this dataset that can be treated as complete. Filing counts for 2025 and 2026 will keep rising as publications catch up, since publication typically lags actual filing by roughly 18 months.
What does US20120219971A1 actually cover, and does it block new biosensor filings?
US20120219971A1, assigned to The Regents of the University of California, claims methods and compositions for detecting dicarboxylic acids using a transcription-factor biosensor, published 2012-08-30. It is a foundational transcription-factor biosensor filing, meaning later work using a transcription-factor architecture for dicarboxylic acid or structurally similar analyte detection should be checked against its specific claim language rather than assumed to be clear. It does not, on its own, cover riboswitch-based or purely enzymatic detection approaches, which sit outside its stated claim scope.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Biosensors and Metabolite Detection covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.